Hebei Changshan Biochemical Pharmaceutical Co Ltd Class A 300255
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- CNY 9.48
- Day Range
- CNY 9.61–10.08
- 52-Week Range
- CNY 4.30–17.98
- Bid/Ask
- CNY 9.92 / CNY 9.93
- Market Cap
- CNY 9.13 Bil
- Volume/Avg
- 21.2 Mil / 34.3 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 7.57
- Dividend Yield (Trailing)
- 0.05%
- Dividend Yield (Forward)
- 0.05%
- Total Yield
- 0.05%
Company Profile
Hebei Changshan Biochemical Pharmaceutical Co Ltd is a biotech high-tech enterprise. It is mainly engaged in the research, development, production, and sale of heparin series products. Some of the company's products are Reserpine sodium, Hyaluronic acid, Heparinoid, Heparin sodium, Tinzaparin sodium, Aspirin enteric-coated tablets, and Yihaitang.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Core
- Total Number of Employees
- 1,424
- Website
- http://www.hbcsbio.com
Comparables
Valuation
|
Metric
|
300255
|
688639
|
688506
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 30.06 | 19.02 |
Price/Book Value | 5.21 | 7.26 | 16.10 |
Price/Sales | 7.57 | 6.82 | 14.07 |
Price/Cash Flow | 36.79 | 130.83 | 16.77 |
Price/Earnings
300255
688639
688506
Financial Strength
|
Metric
|
300255
|
688639
|
688506
|
|---|---|---|---|
Quick Ratio | 0.33 | 0.36 | 0.69 |
Current Ratio | 1.19 | 0.62 | 0.94 |
Interest Coverage | −13.09 | 30.56 | −21.76 |
Quick Ratio
300255
688639
688506
Profitability
|
Metric
|
300255
|
688639
|
688506
|
|---|---|---|---|
Return on Assets (Normalized) | −24.73% | 14.17% | 166.42% |
Return on Equity (Normalized) | −53.95% | 25.94% | 307.42% |
Return on Invested Capital (Normalized) | −25.87% | 18.25% | 219.82% |
Return on Assets
300255
688639
688506
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Ztxxtyvxkf | Ctg | $639.9 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Rmhnpxfw | Tkgtzy | $124.7 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Mpsgzqbm | Vwnjyd | $110.5 Bil | |||
| Moderna Inc
MRNA
| Zxvvqxv | Qfcjz | $57.9 Bil | |||
| BioNTech SE ADR
BNTX
| Jwthkpmf | Hdhw | $24.2 Bil | |||
| argenx SE ADR
ARGX
| Btbvyhkn | Zcblh | $22.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Lxpzkrq | Knrgrhl | $19.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Dcpyllj | Wgsvmx | $15.3 Bil | |||
| Incyte Corp
INCY
| Pwpjczvph | Jpsyyyl | $13.3 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Rgbldtzh | Zhfqqc | $12.4 Bil |